Official tally hits grim milestone as virus outruns containment in conflict zones.
Health teams in eastern Democratic Republic of Congo are racing against a virus that keeps pulling ahead. Confirmed Ebola cases have climbed past 4,000 for the first time in the current outbreak, according to government data released Thursday.
The country’s public health institute reported 4,053 infections and 1,850 deaths. Nearly 700 patients remain in isolation or hospital care, while about 793 people have recovered. The epidemic, declared on May 15, is already the world’s second-largest Ebola outbreak on record and the largest ever recorded in Congo, where the virus was first identified in 1976. Experts call it the fastest-spreading Ebola epidemic documented.
Virus Circulates for Months Before Detection
Researchers believe the Bundibugyo strain began circulating in Ituri province as early as January. A Science journal report identified more than 500 suspected cases before the official declaration. Delayed detection, limited surveillance, and the absence of approved vaccines or specific treatments for this rarer strain allowed the virus to gain ground quickly.
Cases now span five provinces: Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo. Ituri remains the epicenter, accounting for the vast majority of infections across more than 50 health zones.
Conflict and Displacement Fuel Spread
Armed conflict, large-scale population displacement, and movement linked to artisanal gold mining have complicated every containment step. Many patients arrive at treatment centers only in advanced stages of illness. Contact tracing remains incomplete in key areas. Médecins Sans Frontières reported that in its Bunia center, 90 percent of admitted patients had not been identified as contacts beforehand.
MSF described the situation on Wednesday as “more critical than ever,” noting the outbreak shows no sign of slowing. “The international medical response must scale-up without delay,” the organization said.
Africa CDC Director-General Jean Kaseya has repeatedly flagged gaps in contact tracing and high numbers of community deaths. He noted that many new cases lack clear links to known contacts, a sign the virus is moving through communities faster than responders can track.
Experimental Tools Enter the Fight
No licensed vaccine or targeted treatment exists for Bundibugyo. Trials of experimental options, including remdesivir, the monoclonal antibody cocktail MBP-134, and post-exposure prophylaxis with obeldesivir, are underway in Ituri. Africa CDC has also begun limited use of the existing Ervebo vaccine, developed for the Zaire strain, after early observations of reduced deaths among vaccinated individuals. Specific Bundibugyo vaccine candidates have entered early human trials in the UK and Canada.
True case numbers may be significantly higher than the official count. WHO and local officials have warned that underreporting remains a serious risk in remote and insecure areas.
The human cost continues to mount among displaced families and communities already strained by years of violence. Health workers face both the virus and the daily reality of insecurity. Containing this outbreak will require sustained international support, stronger community trust, and faster delivery of resources to the front lines.